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Abstract
Unsuppressed hepatic glucose production (HGP) contributes significantly to glucose intolerance 
and diabetes, which can be modeled by genetic inactivation of hepatic insulin receptor substrate 
(Irs) 1 and Irs2 (LDKO-mice). We previously showed that glucose intolerance in LDKO-mice is 
resolved by hepatic inactivation of the transcription factor FoxO1 (i.e., LTKO-mice)—even though 
the liver remains insensitive to insulin. Here, we report that insulin sensitivity in the white adipose 
tissue (WAT) of LDKO-mice is also impaired, but is restored in LTKO-mice in conjunction with 
normal suppression of HGP by insulin. To establish the mechanism by which WAT insulin 
signaling and HGP were regulated by hepatic FoxO1, we identified putative hepatokines—
including excess follistatin (Fst)—that were dysregulated in LDKO-mice but normalized in LTKO-
mice. Knockdown of hepatic Fst in the LDKO-liver restored glucose tolerance, WAT insulin 
signaling, and the suppression of HGP by insulin; however, expression of Fst in the liver of 
healthy LTKO-mice had the opposite effect. Of potential clinical significance, knockdown of Fst 
also improved glucose tolerance in high-fat fed obese mice, and serum FST was reduced in 
parallel with glycated hemoglobin in obese individuals with diabetes who underwent therapeutic 
gastric bypass surgery. We conclude that follistatin is a pathological hepatokine that might be 
targeted for diabetes therapy during hepatic insulin resistance.
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Introduction
The complex pathophysiology of type 2 diabetes (T2D) arises from cell-autonomous 
consequences of insulin resistance that can propagate among heterologous tissues through 
dysregulated lipid flux1–3, bile acids or circulating intermediary metabolites4, as well as 
dysregulated production and secretion of cytokines, adipokines and hepatokines3,5,6. 
Although T2D is characterized by systemic insulin resistance, disruption of hepatic insulin 
signaling alone recapitulates many aspects of T2D7, including enhanced endogenous glucose 
production (EGP)8. Though EGP includes renal and intestinal contributions9, it is mainly a 
function of hepatocytes. Hepatic glucose production (HGP) is suppressed directly by insulin 
via inhibition of hepatic glycogenolysis and gluconeogenesis, and indirectly by insulin-
mediated suppression of adipose tissue lipolysis, glucagon secretion, and neuronal signals8.
The proteins insulin receptor substrate (Irs) 1 and Irs2 link the activated insulin receptor 
kinase (IRK) to the PI3K→Akt cascade, which regulates the expression of hundreds of 
hepatic genes by inactivating Forkhead box O (FoxO) family transcription factors10,11. We 
previously investigated the consequences of hepatic Irs1 and Irs2 deletion in LDKO 
(Irs1L/L•Irs2L/L•CreAlb)-mice and the complementary LTKO (Irs1/2L/L•FoxO1L/L•CreAlb)-
mice12. In addition to dysregulated hepatic metabolism and mitochondrial dysfunction13, 
LDKO-mice develop systemic metabolic disease—including glucose intolerance, 
hyperinsulinemia and dysregulated energy homeostasis12,14. Remarkably, hepatic and 
systemic dysregulation is largely corrected upon further genetic deletion of hepatic FoxO1 in 
the LDKO-mice—despite continued persistent and complete hepatic insulin resistance12,13. 
These findings are confirmed and extended by others using compound hepatic-specific 
IRK•FoxO1- or Akt1•Akt2•FoxO1-knockout mice1,15–17. The normalization of HGP in 
these models owes, at least partially, to the re-sensitization of white adipose tissue (WAT) to 
insulin, which indirectly reduces hepatic gluconeogenesis by decreasing substrate 
availability and down-regulating hepatic pyruvate carboxylase activity1.
In models of complete hepatic insulin resistance (including LTKO-mice), genetic disruption 
of hepatic FoxO1 substantially normalizes the expression of hundreds of dysregulated 
hepatic genes12,16. Within such mice, FoxO1-dependent gene expression, or metabolic 
signals generated in hepatocytes, could reasonably contribute to dysregulation of peripheral 
insulin sensitivity and promote the delivery of metabolic intermediates to the liver—
including excess glycerol and free fatty acids (FFAs) from adipose tissue3. Thus, while 
failing to restore hepatic insulin signaling per se, disruption of hepatic FoxO1 in LDKO-
mice (i.e., LTKO-mice) and similar models effectively restores glucose tolerance12,15,17,18. 
Just how hepatic FoxO1 disruption might prevent the manifestation of peripheral insulin 
resistance has remained unclear.
Comprehensive analyses of gene expression reveals various genes encoding secreted 
proteins expressed in the human liver (so-called hepatokines), some of which might affect 
glucose and lipid metabolism5,6,19. We hypothesized that FoxO1-dependent dysregulation of 
hepatokines in LDKO-liver might promote peripheral insulin resistance—and substantially 
underlie the restoration of metabolic homeostasis in LTKO-mice. In this report, we use the 
LDKO- and LTKO-mice to identify follistatin (Fst)—best known for its modulation of TGF-
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β superfamily members20,21—as a key FoxO1-dependent hepatokine that can dysregulate 
WAT insulin sensitivity and hepatic gene expression to propagate systemic metabolic disease 
during hepatic insulin resistance.
Results
Hepatic Foxo1 is required for excess HGP and glucose intolerance during hepatic insulin 
resistance
Lipolysis of WAT triglycerides—which is suppressed by insulin—indirectly promotes 
hepatic gluconeogenesis1. To establish whether WAT insulin resistance alone dysregulates 
systemic glucose tolerance, we produced FDKO-mice by intercrossing Irs1L/L•Irs2L/L-mice 
(Cntr) with adipose-specific CreAdipo-mice (adiponectin promoter-driven Cre mice) to delete 
Irs1 and Irs2 specifically in adipocytes (Supplemental Fig. 1a). Compared to floxed Cntr or 
LDKO-mice (Irs1L/L•Irs2L/L•CreAlb), the FDKO-mice displayed normal glucose tolerance 
(Supplemental Fig. 1b), a result that is similar to mice lacking the adipocyte insulin receptor 
(FIRKO-mice)22 or adipocyte Akt1 and Akt223. Thus, dysregulation of the 
IR→IRS1/2→PI3K→Akt cascade in WAT alone was insufficient to dysregulate systemic 
glucose homeostasis during the intraperitoneal glucose tolerance test (GTT).
To understand the requirement of hepatic insulin signaling for systemic glucose homeostasis, 
we investigated glucose tolerance and HGP in LDKO-mice and LTKO-mice12. As shown 
previously, LDKO-mice developed glucose intolerance, which was corrected in the LTKO-
mice (Supplemental Fig. 1b,c). Since excess HGP contributes to systemic glucose 
dysregulation, we used a hyperinsulinemic-euglycemic clamp to compare HGP in LDKO- 
and LTKO-mice. The glucose infusion rate (GIR) required to maintain euglycemia during 
insulin infusion (4 mU/kg/min) was significantly greater in Cntr-mice than in LDKO-mice 
(Fig. 1a); however, the GIR was normal in the LTKO-mice, despite the absence of hepatic 
Irs1 and Irs2 (Fig. 1b). Moreover, insulin failed to suppress HGP in LDKO-mice, whereas 
HGP was suppressed normally by insulin in LTKO-mice (Fig. 1c,d). Thus, hepatic insulin 
signaling was dispensable for glucose tolerance and regulation of HGP when hepatic FoxO1 
was inactivated.
Hepatic FoxO1 dysregulates WAT insulin signaling
Normal suppression of HGP in LTKO-mice suggested that insulin indirectly suppressed 
HGP through its effects on white adipose tissue or other tissues. To investigate insulin 
signaling in the extra-hepatic tissues of LDKO-mice, we measured Akt phosphorylation 
(pS473Akt and pT308Akt) in the skeletal muscle, epigonadal white adipose tissue (eWAT), 
inguinal WAT (iWAT) and brown adipose tissue (BAT) upon completion of the 
hyperinsulinemic-euglycemic clamp. Compared with Cntr-mice, LDKO-mice showed 
reduced pS473Akt and pT308Akt in eWAT, iWAT and BAT, with insignificant changes in 
skeletal muscle (Supplemental Fig. 1d–f). By contrast, pS473Akt and pT308Akt 
phosphorylation were normal in eWAT and iWAT isolated from LTKO-mice (Supplemental 
Fig. 1g–i). Moreover, by comparision against Cntr-mice, insulin-stimulated Irs1•p110PI3K 
complex formation significantly decreased (by 49%) in eWAT of LDKO-mice, whereas the 
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association was normal in eWAT of LTKO-mice (Fig. 1e). These results suggest that hepatic 
FoxO1 promoted WAT insulin resistance in LDKO-mice.
To determine if adult-onset hepatic insulin resistance promoted FoxO1-dependent WAT 
insulin resistance, LDKO-mice were created acutely by infecting Irs1L/L•Irs2L/L-mice with 
CreAAV•TBG (adeno-associated virus encoding Cre recombinase, driven by the hepatocyte-
specific thyroid-binding globulin (TBG) promoter) or control GFPAAV•TBG. Like LDKO-
mice, Irs1L/L•Irs2L/L•CreAAV•TBG-mice displayed low levels of hepatic Irs1 and Irs2 
proteins and developed glucose intolerance (Supplemental Fig. 2a,b). Conversely, glucose-
tolerant adult LTKO-mice infected with FoxO1AdV (adenovirus encoding FoxO1) developed 
glucose intolerance (Supplemental Fig. 2c,d). Consistently, insulin-stimulated Irs1•p110PI3K 
complex formation decreased significantly in eWAT of both Irs1L/L•Irs2L/L•CreAAV•TBG-
mice and LTKO•FoxO1AdV-mice (Fig. 1f,g). Thus, hepatic FoxO1 promoted adipose tissue 
insulin resistance following acute loss of hepatic insulin signaling.
Next, we investigated the activation state of hormone-sensitive lipase (Hsl) in eWAT by 
measuring the phosphorylation of this protein. Compared with Cntr-mice, pS660Hsl was 
higher in the eWAT of LDKO-mice during fasting and insulin-stimulated conditions; 
however, pS660Hsl was indistinguishable in eWAT from LTKO-mice and the litter-matched 
controls (Cntr3) during insulin stimulation (Supplemental Fig. 2e). Consistent with these 
results, insulin failed to suppress circulating FFAs in LDKO-mice but suppressed FFAs 
normally in LTKO-mice (Supplemental Fig. 2f,g). Moreover, compared to control mice, 
H&E staining revealed smaller adipocytes in the eWAT from LDKO-mice and 
LTKO•FoxO1AdV-mice (Supplemental Fig. 2h). These results suggest that hepatic FoxO1 
suppressed indirectly Irs1→PI3K→Akt─┤Hsl signaling in the eWAT of LDKO-mice.
Finally, we compared RNA expression profiles of eWAT obtained from Cntr- and LDKO-
mice, and Cntr3- and LTKO-mice. Compared against the controls, the expression of 82 
genes decreased, and 83 genes increased more than 2-fold in eWAT of LDKO-mice, most of 
which returned to normal expression in eWAT of LTKO-mice (Supplemental Fig. 2i and 
Supplemental Table 1). These results suggest that disruption of hepatic Irs1 and Irs2 
promotes FoxO1-dependent gene expression changes in eWAT, which might integrate with 
hepatic dysfunction to dysregulate systemic glucose homeostasis. Indeed, CreAAV•TBG -
mediated deletion of hepatic Irs1 and Irs2 in the FDKO-mice caused fasting hyperglycemia 
and severe glucose intolerance (Fig. 1h,i), suggesting that hepatic and adipose insulin 
resistance synergistically disrupt glucose homeostasis (Supplemental Fig. 2j).
Identification of FoxO1-dependent hepatokines in LDKO-mice
Previous work suggests that inflammatory cytokines might dysregulate systemic glucose 
metabolism24. We measured the circulating concentrations of several cytokines in LDKO- 
and LTKO-mice—including TNFα, IL-6, IL-1β, IL-2, IL-4, IL-5, KC and MIP1a; however, 
only IL-6 displayed significant FoxO1-dependent elevation (Supplemental Fig. 3a–h). We 
generated LDKO•IL-6−/−-mice to test whether IL-6 contributed to glucose intolerance and 
WAT insulin resistance; however, glucose intolerance was not normalized in LDKO•IL-6−/−-
mice compared against Cntr•IL-6−/− (Supplemental Fig. 3i). Furthermore, insulin-stimulated 
formation of the Irs1•p110PI3K complex remained low in eWAT from LDKO•IL-6−/−-mice 
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(Supplemental Fig. 3j). We conclude that elevated IL6 was not responsible for dysregulated 
glucose homeostasis and eWAT insulin resistance in LDKO-mice.
To test whether serum from LDKO-mice contains hepatic-derived circulating factors that 
modulate peripheral insulin action, cultured 3T3-L1 adipocytes were treated for 24 hours 
with 5% mouse serum obtained from LDKO- or Cntr-mice and then incubated briefly with 
insulin. Serum from the LDKO-mice significantly reduced (by 51%) the formation of the 
Irs1•p110PI3K complex, whereas heat-inactivated serum had no effect (Fig. 2a). These data 
suggest that heat-labile circulating protein(s) or other factor(s) in LDKO-mice might inhibit 
insulin signaling in adipose tissues.
To find hepatokines that promote systemic insulin resistance in LDKO-mice, we used 
published Affymetrix microarray data to identify the liver genes that were higher or lower (≥ 
3-fold, FDR<0.05) in LDKO-mice compared to Cntr-mice (Array Express accession #E-
MEXP-1649)12. We further selected the genes that changed in LDKO-mice but were 
expressed normally in LTKO-mice, and filtered this subset against a curated list of secreted 
proteins that was confirmed by Ingenuity Pathway Analysis. This strategy revealed 19 
putative hepatokines that were ≤ 3-fold lower, and 66 that were ≥ 3-fold higher in LDKO-
mice (Fig. 2b,c). Some of these hepatokines might have effects upon peripheral metabolism
—including higher lipoprotein lipase (Lpl; facilitates triglyceride uptake), follistatin (Fst; 
inhibits TGFβ→Smad signaling25), or insulin-like growth factor binding protein 1(Igfbp1; 
inhibits Igf1 signaling); or lower insulin-like growth factor 1 (Igf1; reduced body growth). 
Thus, we infected wild-type (WT) mice maintained on a high fat diet (HFD) with AAVTBG 
vectors encoding several candidate hepatokines or a control GFPAAV•TBG. The first cohort—
including growth hormone receptor (Ghr), glutathione peroxidase 3 (Gpx3), serine peptidase 
inhibitor, clade B, member 6a (Serpinb6a), myelin protein zero like 1(Mplz1) or 
neurotrophin 3 (Ntf3)—had no effects on fasting glucose levels, insulin levels, glucose 
tolerance or insulin tolerance (Supplemental Fig. 4a–f). In the second cohort leukocyte 
elastase inhibitor A (Serpinb1a) and serum amyloid a4 (Saa4) decreased glucose without an 
effect upon serum insulin, whereas Igf1 and inhibin E (Inhbe) increased serum insulin levels 
without effects on glucose (Fig. 2d,e). However, Fst315 (circulating follistatin) increased 
circulating glucose and insulin, and the homeostatic model assessment of insulin resistance 
(HOMA-IR) suggested that Fst315 promoted systemic insulin resistance (Fig. 2d–f). Fst315 
also promoted significant insulin resistance during the insulin tolerance test (ITT) (Fig. 2g). 
Most of the tested hepatokines had an insignificant effect upon glucose tolerance; however, 
Fst315 impaired glucose tolerance significantly and Lpl significantly improved glucose 
tolerance (Fig. 2h,i). Finally, we confirmed expression of the virus-encoded hepatokine 
genes in liver by qPCR (Supplemental Fig. 4g,h). Fst315AAV•TBG infection of Cntr-mice on 
a HFD increased circulating Fst315 23-fold (Fig. 2j).
To determine whether a physiological 2-fold increase circulating Fst could dysregulate 
glucose tolerance, C57BL6 mice on a HFD for 2 months were infected with a lower dose of 
Fst315AVG•TBG or control GFPAAV•TBG. Ten days after Fst315AVG•TBG infection, circulating 
Fst was 2.2-fold higher than in controls, which still elevated fasting glucose and impaired 
glucose tolerance (Supplemental Fig. S4i–k). Together these results suggest that Fst315 
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contributed—at least in part—to the hepatic FoxO1-dependent WAT insulin resistance and 
glucose intolerance in LDKO-mice.
FoxO1 regulates Fst expression in LDKO-mice
Two Fst isoforms are generated by alternative mRNA splicing, including membrane-bound 
(autocrine) Fst288 and the longer circulating (endocrine) Fst315 (ref. 21). Compared to fed 
Cntr-mice, hepatic Fst mRNA (total and Fst315) and circulating Fst protein was 2-fold 
higher during fasting, and 6-fold higher during STZ-induced type 1 diabetes (Supplemental 
Fig. 5a–e). This pattern of expression was consistent with previous work showing that 
hepatic Fst is upregulated by an elevated glucagon/insulin ratio25. Although this ratio was 
relatively low in LDKO-mice—glucagon was elevated 4-fold while insulin was elevated 20-
fold (Supplemental Fig. 5f,g)—the LDKO-liver fails to respond to insulin, so the effect of 
glucagon might be exaggerated. Compared to Cntr-liver, mRNA in LDKO-liver encoding 
Fst288 and Fst315 increased 10- and 30-fold (Fig. 3a). Moreover, the concentration of 
circulating Fst in fasted LDKO-mice increased 20-fold, and immunostaining revealed more 
Fst protein in liver sections (Fig. 3b,c). Fst mRNA was also higher in the liver of hepatocyte-
specific insulin receptor knockout mice (LIRKO-mice), confirming that hepatic insulin 
signaling suppressed Fst expression (Supplemental Fig. 5h). Consistent with these results, 
serum Fst was ~2-fold higher in genetically obese mice (ob/ob) or Cntr-mice fed a HFD 
(Supplemental Fig. 5i), which can be expected to impair glucose tolerance (Supplemental 
Fig. 4j).
Circulating and hepatic Fst levels were normal in the LTKO-mice suggesting that FoxO1 
promoted its expression during hepatic insulin resistance (Fig. 3a,b). Moreover, infection of 
primary hepatocytes from C57BL6 mice with shFoxO1AdV decreased glucagon-stimulated 
Fst, compatible with a role for FoxO1 in stimulation by a high glucagon/insulin ratio (Fig. 
3d). Consistent with these results, FoxO1AdV increased Fst mRNA and protein concentration 
in cultured hepatocytes and increased the concentration of Fst secreted into the medium 
(Fig. 3e). By contrast, infection with shFoxO1AdV decreased Fst mRNA and the 
concentration of Fst protein in cultured hepatocytes and in the medium (Fig. 3f).
Finally, we used chromatin-immunoprecipitation (CHIP) with a FoxO1 antibody to 
determine whether FoxO1 binds directly to the Fst promoter. By comparison with strong 
FoxO1 binding to the Pck1 promoter (positive control), or weak background binding to the 
Gapdh promoter (negative control), FoxO1 bound significantly between −525 to −2175 of 
the Fst promoter (Fig. 3g). These regions contain several consensus FoxO1 binding sites that 
are homologous among human, mouse and rat supporting the hypothesis that nuclear FoxO1 
is an important regulator of Fst expression (Supplemental Fig. 5j).
Bariatric surgery reduces FST in obese individuals with diabetes
Previous reports show that plasma Fst is elevated in individuals with type 2 diabetes25,26. To 
investigate the relation between glucose dysregulation and FST in humans, we measured 
circulating FST concentration in a group of obese individuals with diabetes (BMI: 45.5±3, 
%HbA1c: 8.4±1) before and after treatment by Roux-en-Y gastric bypass surgery (RYGB) 
(Supplemental Table 2).
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Six months after RYGB, %HbA1c decreased significantly to 6%, confirming a beneficial 
effect upon glycemic control (Fig. 3h). Moreover, the serum FST concentration correlated 
positively with declining %HbA1c (Pearson correlation: r = 0.5977, P = 0.0088) as it 
decreased significantly by 48% six months after RYGB (Fig. 3i). Importantly, the FST 
concentration changed within the biologically active range (Supplemental Fig. 4i–k). Thus, 
the beneficial effect of RYGB might be related, at least in part, to reduced circulating FST.
Knockdown of hepatic Fst promotes WAT insulin sensitivity and reduces HGP
To establish whether excess endogenous hepatic Fst promotes WAT insulin resistance, we 
deleted hepatic Fst alleles by infecting LDKO-liver with CRISPR/Cas9-based AAV bearing 
two different guide RNAs targeting Fst (designated sgFst1AAV•TBG or sgFst2AAV•TBG). 
Compared to the control nullAAV•TBG vector, sgFst2AAV•TBG significantly reduced total 
hepatic and circulating Fst 2-fold, whereas sgFst1AAV•TBG produced an intermediate effect 
that did not reach significance (Fig. 4a,b). Consistent with the differential reduction of Fst in 
liver using these two different guide RNAs, glucose tolerance reached the normal range in 
LDKO•sgFst2AAV•TBG–mice, whereas LDKO•sgFst1AAV•TBG–mice displayed an 
intermediate but insignificant reduction (Fig. 4c). A similar differential effect on serum 
insulin levels was also observed with the two guide RNAs versus control (Fig. 4d). 
Compared to nullAAV•TBG-mice, eWAT from LDKO•sgFst2AAV•TBG-mice displayed greater 
Irs1•p110PI3K complex formation and Akt phosphorylation (pT308Akt and pS473Akt) (Fig. 
4e–g); however, pS660Hsl was significantly lower in both LDKO•sgFst1AAV•TBG-mice and 
LDKO•sgFst2AAV•TBG-mice compared to the control (Fig. 4f,g).
The intermediate response to sgFst1AAV•TBG infection appears to arise from its variable 
infection or effect upon Fst levels. To confirm the relation between circulating Fst and the 
biological responses, we calculated Pearson correlation coefficients for the combined groups 
of mice. Significant correlations were calculated in all cases: Fst vs Ins: r = 0.93, P < 0.0001; 
Fst vs GTT-AUC: r = 0.763, P < 0.0001; and Fst vs PI3K: r = −0.408, P = 0.0310. Thus, the 
Fst concentration measured across each group (Cntr, null, sgFst1 and sgFst2) correlated 
significantly with each biological response. Taken together, these results suggest that 
lowering hepatic Fst improved insulin sensitivity of eWAT and glucose tolerance in LDKO-
mice.
Since CRISPR/Cas9-based gene editing can produce off-target effects, we used hepatic 
shFstAAV•TBG infection to validate the benefit of reducing hepatic Fst mRNA in LDKO-mice 
(Supplemental Fig. 6a). Compared against the nullAAV•TBG infection, eWAT from 
LDKO•shFstAAV•TBG-mice displayed significantly less hepatic and circulating Fst 
(Supplemental Fig. 6b,c), improved glucose tolerance (Supplemental Fig. 6d), increased Akt 
phosphorylation (pT308Akt and pS473Akt), and decreased pS660Hsl (Supplemental Fig. 
6e,f). Together these results confirm that hepatic-derived Fst promotes glucose intolerance 
and insulin resistance of eWAT in LDKO-mice.
To establish the relationship between hepatic Fst and HGP, hyperinsulinemic-euglycemic 
clamp was conducted on LDKO-mice infected with shFstAAV•TBG or nullAAV•TBG. The GIR 
required to maintain euglycemia was significantly greater in LDKO•shFstAAV•TBG-mice 
versus LDKO•nullAAV•TBG-mice, suggesting that reducing hepatic Fst increased systemic 
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insulin sensitivity (Fig. 4h,i). Compared to the control LDKO•nullAAV•TBG-mice, HGP 
decreased in LDKO•shFstAAV•TBG-mice during the insulin clamp and the suppression of 
HGP by insulin was restored (Fig. 4j,k). Thus, knockdown of hepatic Fst in LDKO mice 
provided a benefit similar to that conferred by genetic disruption of hepatic FoxO1.
To establish whether Fst contributes to glucose intolerance in a non-genetic model of 
diabetes, C57BL6 mice maintained on high-fat diet for two months were infected with 
shFstAAV•TBG or NullAAV•TBG. Serum Fst levels were 37% lower in shFstAAV•TBG mice than 
in the control NullAAV•TBG-mice (Fig. 4l). Suppression of hepatic Fst resulted in 
significantly lower circulating glucose before and during the GTT compared to control-
treated mice (Fig. 4m, n). Thus, hepatic Fst promoted glucose intolerance during genetic or 
physiological diabetes.
Fst promotes WAT insulin resistance and HGP in WT mice
Next, we investigated directly whether circulating Fst in LDKO-mice can dysregulate 
adipose insulin signaling. Cultured 3T3-L1 adipocytes were incubated with mouse serum 
obtained from Cntr- or LDKO-mice, then treated briefly with insulin. Compared with serum 
from Cntr-mice, serum from LDKO-mice resulted in significantly lower (by 37%) insulin-
stimulated p110PI3K•Irs1 complex formation; moreover, addition of an antibody to neutralize 
Fst in the LDKO serum resulted in greater p110PI3K•Irs1 complex formation that 
approached the normal range (Fig. 5a).
To test whether Fst315 induced WAT insulin resistance in WT mice, C57BL6 mice 
maintained on a HFD for four months were infected with control GFPAAV•TBG or 
Fst315AAV•TBG. C57BL6•Fst315AAV•TBG-mice displayed less 2-DOG ([1-14C] 2-deoxy-D-
glucose) uptake (as a measure of insulin action) into eWAT, iWAT and skeletal muscle upon 
completion of the hyperinsulinemic-euglycemic clamp (Fig. 5b–d); however, uptake by BAT 
was not affected (Fig. 5e). Both pT308Akt and pS473Akt were significantly higher while 
pS660Hsl was significantly lower in eWAT of C57Bl/6•Fst315AAV•TBG mice (Fig. 5f,g). 
Unlike Fst315, Fst288 has a functional heparin binding domain that can anchor it to the cell 
membrane upon secretion, where it might compete with receptors for binding TGFβ-
superfamily ligands27. We placed C57BL6 mice on a HFD for two months and then infected 
them with Fst288AAV•TBG. Four weeks later, hepatic Fst288 mRNA and protein were 128-
fold and 4-fold higher, respectively, than in control mice (Supplemental Fig. 7a,b). 
Unexpectedly, circulating Fst was elevated 12-fold one week after infection indicating that 
hepatic Fst288 entered the circulation (Supplemental Fig. 7c). Compared to control 
C57BL6•GFPAAV•TBG-mice on the HFD, fasting plasma insulin and blood glucose 
concentrations increased significantly in C57BL6•Fst288AAV•TBG-mice (Supplemental Fig. 
7d,e), which also developed glucose intolerance (Supplemental Fig. 7f). Fst288AAV•TBG 
infection resulted in a 2-fold lowering of 2-DOG uptake into eWAT and iWAT upon 
completion of hyperinsulinemic-euglycemic clamp (Supplemental Fig. 7g,h).
We next conducted hyperinsulinemic-euglycemic clamps to measure HGP in C57BL6 mice 
infected with GFPAAV•TBG, Fst315AAV•TBG or Fst288AAV•TBG. On a HFD, the GIR required 
to maintain euglycemia during the clamp in the GFPAAV•TBG-infected mice was 
significantly higher than in either Fst315AAV•TBG- or Fst288AAV•TBG-mice (Fig. 5h,i and 
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Supplemental Fig. 7i,j). Moreover, hepatic expression of either Fst315 or Fst288 increased 
HGP during basal and clamp conditions, and strongly reduced the ability of insulin to 
suppress HGP (Fig. 5j,k and Supplemental Fig. 7k,l).
Compared to fasted Cntr-mice on the HFD, insulin failed to suppress circulating FFA in 
fasted C57BL6•Fst315AAV•TBG-mice maintained on HFD (Fig. 5l). To confirm the 
inhibitory effect of Fst upon the suppression of lipolysis, metabolically normal LTKO-mice 
were infected with Fst315AAV•TBG or control GFPAAV•TBG. Two weeks later, FFA levels 
after insulin treatment (1U/kg) decreased normally in the Cntr-mice, but only weakly in the 
LTKO-Fst315AAV•TBG mice (Fig. 5m). As in LDKO-mice, urinary ketones were greater in 
the LTKO•Fst315AAV•TBG mice than in Cntr-mice (Fig 5n,o). These results are consistent 
with unsuppressed lipolysis owing to Fst-induced WAT insulin resistance.
Regulation of hepatic gene expression by Fst depends partially on hepatic FoxO1
To investigate how Fst affects hepatocytes per se, we used Affymetrix microarrays to 
quantitate liver mRNAs from fasted mice infected with Fst288AAV•TBG or GFPAAV•TBG 
(Supplemental Fig. 8a). Fst288AAV•TBG infection modestly up- or down-regulated the 
expression of many genes, including several related to hepatic glucose metabolism (Pck1, 
G6pc and Gck) (Supplemental Fig. 8a), while qPCR confirmed that Fst288AAV•TBG affected 
the expression of these and other genes during both fasting (Pck1, G6pc and Gck) and 
feeding (Foxo1, Igfbp1, Pck1, and Ppargc1a) (Fig. 6a,b). We also found that Fst288 
expression was associated with a significant increase in glucose-6-phosphatase enzyme 
activity (encoded by G6pc) during fasting, which is essential for increased HGP (Fig. 6c). 
Microarray analysis revealed that Fst288 modestly down-regulated several lipid and 
cholesterol synthetic genes (Supplemental Fig. 8a). We used qPCR to confirm that Fst288 
reduced the expression of hepatic Srebf1, Fasn, and Hmgcs1 (Supplemental Fig. 8b); 
moreover, immunoblotting showed that Fst288AAV•TBG increased Hsl and decreased Srebp1 
protein in C57BL6 mouse liver (Supplemental Fig. 8c).
Hepatic FoxO1 mediates many effects of insulin upon glucose and lipid metabolism13. To 
determine whether Fst288 modulates FoxO1 cellular distribution, we compared the 
concentration of FoxO1 in nuclear and cytoplasmic fractions of liver lysates from fasting 
and fed C57BL6•Fst288-mice. Compared to control C57BL6•GFP-mice, total FoxO1 
protein was ~2-fold greater in the liver of C57BL6•Fst288-mice (Fig. 6d). Both nuclear and 
cytoplasmic FoxO1 were greater during fasting; however, during feeding nuclear FoxO1 was 
greater while cytoplasmic FoxO1 was lower, opposite to the regulation of FoxO1 by insulin 
(Fig. 6d).
To determine whether Fst288-regulated hepatic gene expression depends upon FoxO1, we 
infected LTKO-mice with Fst288AAV•TBG. RNA expression profiles showed that Fst288 
regulated the expression of genes involved in gluconeogenesis and glycolysis, decreasing 
Gck and increasing Pck1 and G6pc, even without hepatic FoxO1; however, Fst288-mediated 
down-regulation of lipogenic and cholesterogenic genes such as Srebf1 was lost in the 
LTKO-mice (Supplemental Fig. 8a). Next, to determine whether Fst288 required hepatic 
FoxO1 to promote HGP, GTTs and hyperinsulinemic-euglycemic clamp were performed. 
Compared to control GFPAAV•TBG•LTKO-mice, glucose tolerance was impaired mildly in 
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Fst288AAV•TBG•LTKO-mice (Fig. 6e). The GIR required to maintain euglycemia during 
clamp was also much less in Fst288AAV•TBG•LTKO-mice than in GFPAAV•TBG•LTKO-mice 
(Fig. 6f,g). As in LDKO-mice, insulin failed to suppress HGP in the Fst288AAV•TBG•LTKO-
mice (Fig. 6h,i); thus, the detrimental effect of Fst288 upon HGP developed without hepatic 
FoxO1.
Fst–mediated WAT insulin resistance is independent of hepatic FoxO1
Finally, we investigated whether reduced Fst in LTKO-mice contributed to their improved 
glucose tolerance and eWAT insulin sensitivity. We infected LTKO-mice with 
Fst315AAV•TBG to increase circulating Fst315 about 9-fold (Supplemental Fig. 9a). 
Compared to control GFPAAV•TBG•LTKO-mice, the LTKO•Fst315AAV•TBG-mice developed 
profound glucose intolerance that phenocopied LDKO-mice (Supplemental Fig. 9b). During 
insulin stimulation, both pT308Akt and pS473Akt decreased significantly—and pS660Hsl 
increased significantly—in eWAT of LTKO•Fst315AAV•TBG-mice (Supplemental Fig. 9c,d). 
These results suggested that Fst315 promoted WAT insulin resistance independently of 
hepatic FoxO1. Moreover, the GIR required to achieve euglycemia decreased in clamped 
LTKO•Fst315AAV•TBG-mice (Supplemental Fig. 9e,f); and insulin failed to suppress HGP in 
LTKO•Fst315AAV•TBG-mice compared against LTKO•GFPAAV•TBG-mice (Supplemental 
Fig. 9g,h). Thus, FoxO1-dependent glucose dysregulation in LDKO-mice owes, at least in 
part, to FoxO1→Fst regulation rather than hepatic FoxO1 alone.
Discussion
Our results identify the hepatokine Fst as a mediator of systemic metabolic dysregulation 
driven by hepatic FoxO1 activity. Prior investigations have highlighted the FoxO1-dependent 
nature of excessive HGP and/or glucose intolerance in mice with hepatic insulin 
resistance12,15,18. We previously showed that insulin fails to suppress HGP in our LDKO-
mice14; herein, we confirm that HGP suppression is restored in LDKO-mice by disruption of 
hepatic FoxO1 (LTKO-mice). Correlating with HGP, expression and secretion of Fst is 
strongly upregulated in LDKO-liver, but nearly normalized in LTKO-liver. Within primary 
hepatocytes, knockdown of FoxO1 decreases—and its overexpression increases—the 
expression and secretion of Fst. Compatible with direct regulation by FoxO1, we observe 
enriched recovery of Fst promoter regions containing FoxO1 binding motifs. Importantly, 
reducing hepatically-produced Fst in LDKO-mice using CRISPR/Cas9- or Fst shRNA 
mimics the benefits of FoxO1 deletion in LTKO-mice. Conversely, viral expression of Fst in 
the liver of high fat-fed WT mice or chow-fed LTKO-mice reproduces an LDKO-like 
phenotype, including impaired WAT insulin sensitivity, unsuppressed HGP, and severe 
glucose intolerance. Thus, reduced expression and secretion of Fst may largely explain the 
restoration of metabolic homeostasis in LTKO- versus LDKO-mice12. Nonetheless, we do 
not rule out that other liver-intrinsic factors might contribute—particularly as viral 
expression of Fst alters RNA expression profiles in livers of both WT and LTKO-mice.
Although HGP and glucose tolerance are normalized in LTKO-mice, the IRS→PI3K→Akt 
cascade in liver of LTKO-mice remains insensitive to insulin12. Our data support that 
normalization of HGP in LTKO-mice (and similar models) owes substantially to the 
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restoration of WAT insulin sensitivity, which reduces lipolysis and the availability of FFA 
and glycerol that potentiate hepatic gluconeogenesis1,16,17. Demonstrating the negative 
influence of hepatic FoxO1 upon WAT insulin sensitivity, we observe significantly impaired 
IRK→IRS→Akt signaling and Akt→PDE3b─┤HSL signaling in LDKO-WAT, as well as 
impaired insulin suppression of serum FFA—each of which is normalized in LTKO mice.
Within the insulin-resistant liver, excess FFA are oxidized to acetyl-CoA and further 
metabolized to produce ketone bodies28. Our observation of elevated urinary ketones in 
LDKO-mice—but not LTKO-mice—validates the oxidation of excess FFA in the LDKO 
liver to acetyl-CoA, which allosterically upregulates pyruvate carboxylase-dependent 
hepatic gluconeogenesis and HGP1. Forced expression of Fst in LTKO-liver likewise 
increases ketone production, in conjunction with impaired suppression of HGP and glucose 
intolerance. Together, these data support that WAT insulin resistance mediated by Fst 
contributes significantly to glucose intolerance in LDKO-mice12,29–31; however, additional 
secreted or non-secreted hepatic gene products regulated by FoxO1 might combine with Fst 
to produce the systemic effects of severe hepatic insulin resistance (e.g., Patatin Like 
Phospholipase Domain Containing 2 (Pnpla2) and G0/G1 Switch 2 (G0S2)32.
Two Fst isoforms are produced by alternative mRNA splicing: membrane-bound (autocrine/
paracrine) Fst288 that contains a functional heparin binding site; and the longer circulating 
Fst315 that does not21,27,33. Though our assays distinguish the hepatic mRNAs encoding 
these isoforms, available immunoassays cannot distinguish the protein isoforms. Both 
Fst288 and Fst315 mRNAs are upregulated in LDKO versus control or LTKO mice. 
Although its heparin binding domain reportedly anchors Fst288 to cell membranes wherein 
it is produced27, infection with either Fst288AAV•TBG or Fst315AAV•TBG increased 
circulating Fst in LTKO-mice that weakly express endogenous Fst; moreover, the two 
isoforms equivalently dysregulated WAT insulin sensitivity, HGP and glucose tolerance. 
Notwithstanding these results, mice engineered to produce only Fst288—without circulating 
Fst315—were shown earlier to have mildly decreased fasting glucose34. We conclude that its 
over-expression in Fst288AAV•TBG-infected mice confers hepatokine/endocrine function 
upon normally autocrine/paracrine Fst288.
Fst was identified originally as a soluble protein in follicular fluid that suppresses the 
biosynthesis and release from the pituitary of follicle stimulating hormone35. However, Fst 
binds to and neutralizes diverse TGFβ-superfamily ligands. TGFβ-superfamily signaling is 
initiated by heterotetrameric receptor serine kinases, composed of ‘type II’ and ‘type I’ 
receptors that establish the binding specificity and selective phosphorylation of R-Smads—
Smad2 and Smad3 downstream of TGFβ/Activin/Nodal, or Smad1, Smad5 and Smad8 in 
the BMP/GDF pathway; these phosphorylated Smads assemble with Smad4 to enter the 
nucleus and modulate gene expression20,36,37. Fst isoforms bind primarily activin A and B, 
myostatin (GDF8), and with lower affinity BMP4 and BMP11 (refs. 27,34,38,39). 
Circulating follistatin like-3 (Fstl3) binds the same ligands as Fst40 and deletion of Fstl3 
improves glucose tolerance in mice41. Neutralization of activin B might be relevant for 
production of WAT insulin resistance, as it was shown recently to suppress lipolysis in 
mouse embryo fibroblast-derived adipocytes and human adipocytes42. However, as Fst is an 
inhibitor of TGFβ superfamily ligands its activity upon cultured adipocytes might depend 
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upon the mix of TGFβ ligands present in the medium. Moreover, BMP4 was shown to 
suppress lipolysis in pre-adipocytes by inhibiting HSL43. Neutralization of other ligands of 
TGFβ-superfamily receptor Acvr2b could also be involved, since a soluble form of this 
receptor enhances gluconeogenesis in insulin-insufficient mice44.
Future assessment of changes in WAT mRNA transcription caused by ectopic Fst and/or 
TGFβ-superfamily ligands would aid in validating the mechanism by which Fst impairs 
WAT insulin sensitivity. Along these lines, we observe that virus-mediated Fst288 
expression significantly alters the pattern of hepatic gene expression in high fat-fed WT 
mice. Since Fst expression produces a different pattern of hepatic gene expression in the 
LTKO-liver, we suggest, provisionally, that excess circulating Fst may amplify, or alter, 
FoxO1-dependent hepatic gene expression changes. Regardless, as viral expression of Fst 
does not require hepatic FoxO1 to produce an LDKO-like phenotype (i.e., in LTKO-mice), 
Fst-induced changes in hepatic gene expression might be less critical for systemic 
dysregulation than its ability to promote WAT insulin resistance45.
Previously it was reported that insulin resistant individuals and those with T2D exhibit 
modestly elevated circulating FST, and that this increase in FST is positively correlated with 
%HbA1c, fasting glucose and glucose excursion during oral GTT26. While we did not 
measure circulating FST in healthy controls, we found that RYGB surgery significantly 
reduced circulating Fst in obese individuals with diabetes and that this reduction correlated 
with reduced %HbA1c, an indicator of improved medium-term glycemic control. Thus, an 
unknown therapeutic aspect of RYGB might be to reduce the effect of circulating FST upon 
WAT, thereby facilitating control of HGP and glycaemia. Although other interpretations of 
these data are possible, our mouse data support the notion that targeting hepatically-
produced and secreted FST in diabetic adults might prove useful in restoring systemic 
metabolic homeostasis. Because of its clear relation to hepatic insulin resistance and 
possible pleiotropic effects, targeting excess circulating Fst might also prove more fruitful 
than attempts to upregulate TGFβ superfamily-mediated signals in the insulin-resistant WAT.
Online Methods
Mice
We generated the liver-specific Irs1 and Irs2 double knockout (LDKO), and Irs1, Irs2 and 
FoxO1 triple knockout (LTKO) mice as previously described12,13. We purchased C57BL6 
mice (Stock No. 000664), ob/ob mice (Stock No. 000632), B6.129S2-Il6tm1Kopf/J mice 
(Stock No. 002650) and B6;FVB-Tg(Adipoq-cre)1Evdr/J mice (Stock No. 010803) from 
The Jackson Lab. We generated FDKO mice by crossing B6;FVB-Tg(Adipoq-cre)1Evdr/J 
with Irs1 and Irs2 double floxed mice. We generated LDKO:IL6−/− mice by crossing 
B6.129S2-Il6tm1Kopf/J with LDKO mice. All mice were housed in plastic cages on a 12:12 
h light–dark cycle with free access to water and food. We performed animal experiments 
according to all relevant ethical regulations and protocols approved by the Boston Children’s 
Hospital Institutional Animal Care and Use Committee.
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Hyperinsulinemic euglycemic clamp in conscious and unrestrained mice
Prior to the clamp experiment, one catheter was inserted into the right jugular vein for 
infusions. After 5–7 days of recovery, mice that had lost less than 10% of their preoperative 
weight were subjected to the clamp. On the day of the experiment, mice were deprived of 
food for 3.5 hours at 8:00am and then infused continuously with D-[3-3H]-glucose 
(PerkinElmer) (0.05 µCi/min) at a rate of 1ul/min for 1.5 h. After basal sampling from the 
tail vein, a 140min hyperinsulinemic euglycemic clamp was conducted with a primed-
continuous infusion of human regular insulin (4 mU/kg/min, Humulin, Eli Lilly) at a rate of 
2µl/min and continuously with D-[3-3H]-glucose (PerkinElmer) (0.1 µCi/min) at a rate of 
2ul/min throughout the clamp experiment. The insulin solutions were prepared with 3% 
BSA in 0.9% saline. 20% glucose was infused at variable rates as needed to maintain plasma 
glucose at ~130 mg/dl (except in Fig 1D,F(Cntr±SEM: 138±9 mg/dl; LDKO±SEM: 204±21 
mg/dl; P < 0.05)). All infusions were done using micro infusion pumps (KD Scientific). 
Blood glucose concentrations were monitored regularly according to a fixed scheme from 
tail vein. To estimate insulin-stimulated glucose uptake in WAT, BAT and skeletal muscle, 2-
deoxy-D-[1-14C] glucose (10 µCi/mice; PerkinElmer) was administered as a bolus at 95 min 
after the start of clamp. Blood samples (20ul) were taken at −5, 100, 110, 120, 130, and 140 
min of clamp for the measurement of plasma D-[3-3H]-glucose and 2-deoxy-D-[1-14C] 
glucose concentrations. Steady state was considered achieved during 100–140min, when a 
fixed glucose-infusion rate maintained the glucose concentration in blood constantly for 40 
min (see Supplemental Fig. 12). At the end of the experiment, mice were killed by ketamine/
xylazine and WAT, BAT, skeletal muscle and liver were dissected and store at −80°C until 
further analysis.
The D-[3-3H]-glucose and 2-deoxy-D-[1-14C] glucose concentrations in plasma were 
measured according to the procedure of “GLUCOSE CLAMPING THE CONSCIOUS 
MOUSE” from the Vanderbilt-NIDDK Mouse Metabolic Phenotyping Center with some 
modifications. Briefly, 6 µl of plasma sample mixed with 14 µl saline was treated with 100ul 
3N Ba(OH)2 and ZnSO4 (add Ba(OH)2 prior to ZnSO4) and 100 µl of supernatant was 
pipetted into ascintillation vial and dried in oven overnight; 8 ml of scintillation fluid as 
added to the dried vial, or to 50 µl non-dry supernatant for measuring radioactivity in a 
liquid scintillation counter. For measuring 2-deoxy-D-[1-14C] glucose, lysates of adipose 
tissue and skeletal muscle were processed using a perchloric acid Ba(OH)2/ZnSO4 
precipitation46. Glucose uptake into WAT, BAT and skeletal muscle in vivo was calculated 
based on 2-deoxy-D-[1-14C]-glucose 6-phosphate accumulation and specific activity of 2-
deoxy-D-[1-14C]-glucose in serum.
High-fat diet treatment
Wild-type C57BL6 male mice were feed with a high-fat diet (Research Diet: R1245i, 45 
kcal% from fat) for 8–16 weeks.
Glucose tolerance tests (GTT)
For GTTs, mice were fasted, but with free access to water, for 5 hours before the procedure. 
At the start of the procedure, the mice were weighed and a basal glucose levels were 
measured. The mice were then injected intraperitoneally with glucose (2g/kg body weight) 6 
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hours after fasting. Glucose levels were measured again at times 15, 30, 60 and 120 minutes 
after injection.
Insulin tolerance test (ITT)
For ITTs, mice were fasted, but with free access to water, for 4 hours before the procedure. 
At the start of the procedure, the mice were weighed and a basal glucose levels were 
measured. The mice were then injected intraperitoneally with human insulin (1U/kg body 
weight, Humulin, Eli Lilly) 5 hours after fasting. Glucose levels were measured again at 
times 15, 30 and 60 minutes after injection.
Fasting/refeeding experiment
Mice were fasted, but with free access to water, for 16 hours overnight and then fed with 
regular chow diet for 4 hours. Mice were sacrificed after they were anaesthetized with 
ketamine/xylazine and liver and serum were collected for further analysis.
Insulin treatment
In vivo insulin signaling was analyzed 5-min after insulin injection of 1U/kg human insulin 
via vena cava after mice were fasted for 16 hours overnight and anaesthetized with 
ketamine/xylazine. Mice were sacrificed and skeletal muscle, eWAT, iWAT, BAT and liver 
tissues were immediately frozen in liquid nitrogen for further analysis.
Blood Chemistry Analysis
We used commercial ELISA kits to measure circulating insulin and Fst according to the 
manufacturers’ instructions. Insulin kit (80-INSMSU-E01) was purchased from Alpco Inc. 
Fst protein levels were measured using the human Follistatin ELISA kit (R&D Systems, 
DFN00; 22% cross reactivity with mouse Follistatin) following the manufacturer’s protocols 
with some modification. In brief, we applied 150µl mouse serum (150µl vs 100µl) and 
increased the incubation time (overnight vs 2 hours). IL6 protein levels were measured using 
Mouse IL-6 ELISA Kit (Thermo Scientific Pierce, EM2IL6). Blood glucose was measured 
using a glucose meter (Bayer Contour). Urine ketone bodies were measured using 
commercial assay kits (Wako USA, 415-73301 and 411-73401). Serum IL1β, IL2, IL4, IL5, 
KC and MIP1a concentrations were measured using Milliplex MAP mouse magnetic bead 
panel kit.
Primary hepatocytes isolation
Eight to ten-week-old mice were anesthetized by intraperitoneal injection of ketamine/
xylazine (100mg/kg and 10mg/kg body weight). Following anesthesia, the abdominal cavity 
was opened by incisions with scissors and the vena cava and portal vein were located. A 
perfusion catheter was placed into the vena cava. Pre-warmed Liver Perfusion Medium 
(Invitrogen, 17701) (37C) was delivered at 1.6 ml/min for 12 min using a peristaltic pump. 
An incision was made at the portal vein as an outlet for the perfusion solution. Immediately 
following the Liver Perfusion Medium, pre-warmed Liver Digest Medium (Invitrogen, 
17703) (37°C) was delivered at 1.6 ml/min for 12 min using a peristaltic pump. At the end 
of the perfusion, liver was dissected and transferred to a Petri dish on ice containing 10 ml of 
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L-15 medium (Invitrogen, 21083) with 10%FBS. After washing three times with Hepatocyte 
Wash Buffer (Invitrogen, 17704), the primary hepatocytes were re-suspended in William’s E 
medium (Invitrogen, 12551) containing Percoll beads (Sigma, p4937). After 4 hrs incubation 
in William’s E medium containing 10%FBS penecillin and streptomycin, the unattached 
cells were removed, and the dishes were washed with PBS and incubated with maintenance 
media (William’s E medium containing 100µM Dex, Insulin-Transferrin-Selenium, 2mM 
glutamine and PenStrep).
3T3-L1 cell culture
3T3-L1 pre-adipocytes obtained from a mycoplasma-free stock were cultured in 
DMEM/F12 with 10% BCS in 5% CO2. Two days post-confluence, cells were exposed to 
DMEM/10% FBS with isobutylmethylxanthine (0.5 mM), dexamethasone (1 µM) and 
insulin (5 µg/ml). After 2 days, cells were maintained in DMEM/10% FBS until ready for 
treatment at day 7. On day 9, cells were treated with insulin (10nM) for 3min after being 
maintained in DMEM/5% mouse serum for 24 hours.
Luminex Assays
As described previously47,48, the Irs1 capture antibody (rabbit monoclonal antibody 
58-10C-31, Millipore catalog number 05-784R) was coupled to magnetic carboxylated 
microspheres. The p110 subunit of PI3K was detected with antibodies from Cell Signaling 
Technology (CST #4249). For Luminex assays, cell lysates (10 µg) or mouse tissue lysates 
(80 µg) were diluted with Irs1 capture beads (4000 beads/well) into a total volume of 50 µl 
of phosphoprotein detection wash buffer (Bio-rad) and incubated overnight in 96-well round 
bottom plates. After washing twice with the same buffer, the beads were incubated with 50 
µl of detection antibody for 1 h on a rotary plate shaker (80 rpm). After removal of the 
biotinylated detection antibody, the beads were incubated with shaking in 25 µl of 1 µg/ml 
streptavidin-phycoerythrin (Prozyme) for 15 min. All solutions were then removed, and 
beads were suspended in PBS-BN (Sigma) for analysis in a Luminex FlexMap 3D 
instrument.
Histological and immunohistochemical analyses
Liver and WAT were fixed in phosphate buffered paraformaldehyde (10%) and embedded in 
paraffin. H&E staining was conducted by the Pathology Core in Dana-Farber Harvard 
Cancer Center. Fst immunostaining was conducted as described previously2. To probe Fst in 
the liver sections, tissues were deparaffinized in xylene and rehydrated in a series of alcohol/
water mixtures. Antigen retrieval was performed in 10 mM sodium citrate, pH 6.0 for 10 
min. Tissue sections were blocked in 10% normal goat serum, incubated with the primary 
antibodies (Abcam: 203131) overnight at 4°C, goat anti-rabbit secondary antibody 
(Molecular Probes, A11012) for 1 hour at room temperature (25°C). Slide mounting was 
performed using Prolong Antifade Gold with DAPI (Life Technologies, 1652731). 
Composite images were created from a 10 × 10 array of adjacent non-overlapping 10× 
magnification images taken using a Zeiss Axiovert LSM 510 microscope.
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Nuclear and cytoplasmic protein extraction
The nuclear and cytoplasmic proteins were differentially extracted as directed using a kit 
from Thermo Scientific (NE-PER Nuclear and Cytoplasmic Extraction Kit, 78835).
G6Pase activity measurement
G6Pase activity assays were performed as previously described49. Briefly, 100 mg liver was 
homogenized in buffer (Hepes, 5mM; Sucrose, 250 mM) using a dounce homogenizer. 
Microsomes were prepared the using ultracentrifuge at 100,000×g. The reaction was started 
by adding microsomes prep into the substrates mix (G6P: 1–5 mM; sodium cacodylate-,
183.3 mM; Histone Type-IIA, 10mg/ml).
Bypass surgery samples information
Human serum used in this study was obtained as a part of a larger clinical study approved by 
both the Boston Children’s Hospital IRB (IRB-P00021478; PI: Nicholas Stylopoulos) and 
the University of Pittsburgh Medical Center IRB (MOD15090464-02/PRO15090464). 
Informed and consenting individuals underwent RYGB surgery by the Minimally Invasive 
Bariatric and General Surgery (MIBGS) group of the University of Pittsburgh (UPMC). 
Blood was collected by venipuncture at a research visit prior to surgery (baseline) and 6 
months after surgery. Individuals taking Metformin or statins were asked to temporarily 
discontinue these medications starting on the night prior to surgery. Diabetes was defined as 
either a documented fasting blood glucose level >126 mg/dl or a %HbA1c of 6.5 or higher, 
or treatment with an anti-diabetic medication. Mean %HbA1c in diabetic individuals was 
8.35±1.3.
Adenoviral Vector Preparation
To make FoxO1 and GFP overexpression adenoviruses, mouse FoxO1 and GFP coding 
sequences were first subcloned into a pShuttle-IRES-hrGFP-2 vector (Agilent) and then 
transferred to pAdEasy vector (Agilent) as described earlier50. The constructs were digested 
by enzyme PacI (NEB, R0547) and then transfected into human embryonic kidney (HEK) 
293A cells for adenoviral production. To make short hairpin RNA (shRNA) adenovirus to 
knock down Foxo1, a gene-specific shRNA (top strand: 5’ 
GAGCGTGCCCTACTTCAAGGA) was designed using an online tool (BLOCK-iT, Life 
Technologies). The hairpin-encoding oligonucleotides were cloned in vector pENTR/U6 
(Life Technologies), which was recombined with pAd/BLOCK-iT vectors. The positive 
clones were used for transfection of HEK293A cells to make adenoviruses, as previously 
described51.
AAV virus vector preparation
AAV8.TBG.PI.eGFP (GFPAAV•TBG, Lot: AV-8-PV0146), AAV8.TBG.PI.Cre (CreAAV•TBG, 
Lot: AV-8-PV1091) and AAV8.TBG.PI.Null.bGH (nullAAV•TBG, Lot: AV-8-PV0148) were 
purchased from the Vector Core, University of Pennsylvania. To make overexpression AAV 
viruses, mouse genes coding sequences were cloned into a pAAV2 backbone with TBG 
promoter vector and then sent to BCH viral core for AAV2/8 virus production and 
purification. Mouse genes were cloned by PCR using specific primers listed below:
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Cloning primer
Saa4-F AATTGGTACCATGAGGCTTGCCACCGTCATTGTC
Saa4-B ACAAGTCGACCTCAGAACTTCTCAGGAAG
Inhbe-F AATTGGTACCATGAAGCTTCCAAAAGCCCAGC
Inhbe-B ACAAGTCGACCCTAGCTGCAGCCACAGGCCT
Apol7-F TACTTACGCGTACCATGGACACCCCAGACAGAGAA
Apol7-B ACAAGTCGACCTCACTTAGTCAGGCTGTCATGA
Lect1-F AATTGGTACCATGACAGAGAACTCAGACAAA
Lect1-B ACAAGTCGACCTTACACCATGCCCAAGATG
Serpinb1a-F AATTGGTACCATGGAGCAGCTGAGTTCAGC
Serpinb1a-B ACAAGTCGACCCTATGGGGAACAAACCCTGCC
Serpinb6b-F AATTGGTACCATGGATCCACTGCTGGAAGCAAAT
Serpinb6b-B ACAAGTCGACCTCATGGGGAGGAGAACCGACCA
Fst-F AATTGGTACCATGGTCTGCGCCAGGCACCAGCCC
Fst288-B ACAAGTCGACCTCAGTTGCAAGATCCAGAATGC
Fst315-B ACAAGTCGACCTTACCACTCTAGAATGGAA
Lpl-F TATCGCTAGCATGGAGAGCAAAGCCCTGCT
Lpl-B TATGCTCGAGTCAGCCAGACTTCTTCAGAG
Il1rn-F TATCGCTAGCATGACAGCAGCACAGGCTGAGGC
Il1rn-B TATGCTCGAGCTATTGGTCTTCCTGGAAGT
Igf1-F ATCAGCTAGCATGACCGCACCTGCAATAAAGAT
Igf1-B ATCACTCGAGCTACATTCTGTAGGTCTTGT
Ntf3-F TACTTACGCGTACCATGGTTACTTCTGCCACGATCT
Ntf3-B ACAAGTCGACCTCATGTTCTTCCAATTTTTC
Ghr-F ATCAGCTAGCATGGATCTTTGTCAGGTCTT
Ghr-B ATCACTCGAGCTACTGCATGATTTTGTT
Serpinb6a-F AATTGGTACCATGGATCCTCTACAGGAAGCA
Serpinb6a-B ACAAGTCGACCTCAGGGAGAGGAGAACCGGC
Gpx3-F TATCGCTAGCATGGCCCGGATCCTCCGGGCATCCT
Gpx3-B TATGCTCGAGTTACTTCCCCCTGGCGCTCAGGG
Mpzl1-F AATTGGTACCATGGCAGAGGCCGTCGGAG
Mpzl1-B TAGCGGCCGCTTAGTCTTTCCGGATGTCCG
sgFST AAV•TBG—SaCas9 (Cas9 from Staphylococcus aureus) is short enough to be 
delivered with a U6-driven single guide RNA.Plasmid (pX602-AAV-TBG::NLS-SaCas9-
NLS-HA-OLLAS-bGHpA;U6::BsaI-sgRNA, #61593) was purchased from Addgene. To 
make Fst gene knock down AAV viruses, the sgRNAs target to Fst were designed on the 
Broad Institute’s website (sgFST-1: GGAGTGCACATTCGTTGCGGT; sgFST-2: 
GGCACACTCGCTGGCGTATG), purchased from Integrated DNA Technologies, then 
cloned and packaged in BCH viral core.
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shFst AAV•TBG—For preparation of pscAAV-TBG-GFP-shFst, the 377bp CMV promoter 
of pscAAV-GFP (Addgene #32396) was removed (AvrII-BspeI digest) and replaced with a 
706 bp PCR-generated fragment containing the TBG (thyroid binding globulin) promoter 
and paired upstream alpha micro-globulin enhancers. The resulting plasmid was linearized at 
its unique NotI site (between eGFP and SV40 polyA sequences), into which was placed a 
131 bp, EagI-digested synthetic/PCRed cassette containing a 107 bp miRNA-like hairpin 
targeting Fst. Design of the cassette was based on previously described miRNA stem-loop 
sequences and design rules52. The primers of anti-sense Fst sequence are as below:
TBG-ShFst1-TOP:
CGTACGCAGGTACCAGGTGATAGCAATGTCAGCAGTGCCTTTGAATGA
ACAAGAAGAATAAAGTGAAGCCACAGATG
TBG-ShFst1-BOTTOM:
GCTCGGCCGAGCTCGTAGAGTATGGTCAACCTTACTTTTTATTCTTCCT
GTTCATTCACCATCTGTGGCTTCAC
Adenovirus injection and AAV virus injection
Delivery of adenoviral DNA constructs into mouse liver was achieved by intravenous 
injection via the tail vein. Mice were administered with 1× 108 particles of adenovirus per 
gram of body weight in 100–200 microliters saline (0.9% NaCl). Delivery of adeno-
associated virus DNA constructs into mouse liver was achieved by intravenous injection via 
tail vein with 2 × 1011 genome copies (GC) of AAV virus per mice in 100–200 microliters 
saline (0.9% NaCl).
Western blot analysis
Tissue or cells were homogenized in the lysis buffer (50 mm Hepes, pH 7.5, 150 mm NaCl, 
10% glycerol, 1% Triton X-100, 1.5 mm MgCl2, 1 mm EGTA, 10 mm sodium 
pyrophosphate, 100 mm sodium fluoride, and freshly added protease inhibitor cocktail and 
phosphatase inhibitor cocktail). Protein extracts were resolved on an SDS-PAGE gel and 
transferred to nitrocellulose membrane (Bio-Rad). Detection of proteins was carried out by 
incubations with HRP-conjugated secondary antibodies followed by ECL detection reagents. 
Uncropped images can be found in Supplemental Figure. 10,11.
Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed as previously described with minor modifications53,54. Briefly, 
cells were cross-linked with 1% formaldehyde at room temperature for 15 minutes. The 
cross-linking was stopped with 125 mM glycine for 5 min at room temperature. Cells were 
washed with PBS and collected into harvest buffer (100 mM Tris-HCl PH 9.4, 10 mM DTT) 
and incubated on ice for 10 minutes followed by centrifugation at 2000g for 5 minutes. Cells 
then were sequentially washed with ice cold PBS, buffer I (0.25% Triton X-100, 10 mM 
EDTA, 0.5 mM EGTA, 10 mM HEPES, pH 6.5), and buffer II (200 mM NaCl, 1 mM EDTA, 
0.5 mM EGTA, 10 mM HEPES, pH 6.5). Pellets were resuspended in lysis buffer (1% SDS, 
10 mM EDTA, 50 mM Tris-HCl, pH 8.0 supplemented with protease and phosphatase 
inhibitor cocktail (Sigma)) and sonicated to reduce the DNA length to 0.3 to 1.5 kb followed 
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by centrifugation at 8000g for 1 minute at 4C. The soluble chromatin were diluted 10-fold in 
dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.0), 
precleared with sheared salmon sperm DNA and protein A/G sepharose (Santa Cruz 
Biotechnology) at 4oC for one hour. The amounts of chromatin were measured and equal 
amounts of chromatin were used in subsequent IPs with 3 µg of control IgG or FoxO1 
antibody overnight. After immunoprecipitation, 25 µl protein A/G sepharose were added and 
the incubation was continued for another two hours. Precipitates were washed sequentially 
for 5 minutes each in TSE I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 
pH 8.0, 150 mM NaCl) for three times, TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 
20 mM Tris-HCl, pH 8.1, 500 mM NaCl), and TE buffer (10 mM Tris PH 8.0, 1 mM 
EDTA). Precipitates were then eluded with 1% SDS, 0.1 M NaHCO3. Eluates were heated 
at 65°C for overnight to reverse the formaldehyde cross-linking, treated by proteinase K, and 
DNA fragments were purified with a DNA purification Kit (Qiagen). Purified DNAs were 
amplified and quantified using Power SYBR Green PCR Master Mix (Life Technologies) 
and promoter specific primers in QuantStudio 6 Flex. Promoter specific primers are listed 
below:
Chip-PCR primer
mPck1-chip-F TGCAGCCAGCAACATATGAA
mPck1-chip-R TGATGCAAACTGCAGGCTCT
mGapdh-chip-F GCCCTTGAGCTAGGACTGG
mGapdh-chip-R AGGGCTGCAGTCCGTATTTA
Fst-chip-F1 CAAGTGCCTTACCTCCCATT
Fst -chip-R1 TTTTTGCACAGCTGTTGGTT
Fst -chip-F2 TCTAAGCCTTCGTGGTTTTCA
Fst -chip-R2 GGTGACCCCAAAATGTGAAG
Fst -chip-F3 CAAGGTGCAGCTGAAAAACA
Fst -chip-R3 GTTTGGCCTTGTGAATACGG
Fst -chip-F4 AATTTGTATGGGTAGGCCAAA
Fst -chip-R4 GGGGTTGCAGTGTTTCAGAC
Fst -chip-F5 CCTGAGAGCTTGTGTGCACTT
Fst -chip-R5 CCAGAGAAACACCCACCTTC
Fst -chip-F6 GTGGGGACATAGGAAGGTGA
Fst -chip-R6 GCCACTTAACGGCAGAATTT
Fst -chip-F7 CAAGGGGGACAGTTTGCTAT
Fst -chip-R7 CTCTTCCCTCCAACGCATTA
Fst -chip-F8 AGGGAGGAAAAAGCCTGAAG
Fst -chip-R8 GGGGCTTCACATCCTTCTTA
Fst -chip-F9 TGATTCATGCCCACTTTCAA
Fst -chip-R9 CCGAAATACAGCCGTGCTAA
Fst -chip-F10 TTCGCTGTTTGTTGTCGTTC
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Chip-PCR primer
Fst -chip-R10 AACGATTACTTCACGGAAAAGG
Fst -chip-F11 GGGGAGAAAAGAAAGGGAGA
Fst -chip-R11 GCTCCACAAGTCAGAAGCAA
Fst -chip-F12 GGGCAGGGGTTCTACTTTTC
Fst -chip-R12 GGTTCCAACATCTTCCGAGA
Fst -chip-F13 TACCAGCCTTGCTGATAGGG
Fst -chip-R13 GAAATTTCCGAGGGCTGCT
RNA extraction and qPCR analysis
RNA isolation was performed as described previously12. Real time RT-PCR was performed 
in two steps. First, cDNA was synthesized using a cDNA synthesis kit (Bio-Rad). Second, 
cDNA was analyzed by real time PCR using the SYBR Green Master Mix (Applied 
Biosystems). Specific PCR primers are listed below:
Q-PCR primer
Saa4-F AGGTTGTCCCGATAGGCTCT
Saa4-B CCACCGTCATTGTCCTCTG
Inhbe-F CTGGCAACCGAGAGAAAGTC
Inhbe-B TACAGGTGGTGGGACCAAAG
Apol7-F GGTAAGTGTGGTGTCTGCTGA
Apol7-B ATAAAGAAAGAAGT
Lect1-F CCTTCACCTGTGCTTTGATG
Lect1-B ACCTTTAAAATGGGAAGCGG
Serpinb1a-F ACTCTGAAACTTGCTAACAGAC
Serpinb1a-B AGGCATGCAGAAAATCCACA
Serpinb6b-F TCACCCAGTGTTTTCAAAAGG
Serpinb6b-B GCTTGCTGACAGCCTGAAC
Fst288/315-F TGCTCTTCTGGCGTGCTTCT
Fst288-B GGAAAGCTGTAGTCCTGGTCTT
Fst315-B AAATTGCAGAAAGTTCTGA
Lpl-F TCAGCTGTGTCTTCAGGGGT
Lpl-B TTTGGCTCCAGAGTTTGACC
Il1rn-F TCCCAGATTCTGAAGGCTTG
Il1rn-B GTGAGACGTTGGAAGGCAGT
Igf1-F CTTCAGTTCGTGTGTGGA
Igf1-B CACAGTACATCTCCAGTC
Fst-total-F TGCTGCAACACTCTTCCTTG
Fst-total-B TGCTGCTACTCTGCCAGTTC
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Q-PCR primer
Ghr-B GTACTATGCTAAAAGGGAAA
Ghr-B GTTGAAGTAACAGCTGTTTTT
Gpx3-F GATGGTGAGGGCTCCATACT
Gpx3-B CATCCTGCCTTCTGTCCCT
Serpinb6a TAGCACCCTGAAAGTCCAGC
Serpinb6a TTGCTCAGAACAGCCAACAG
Mpzl1-F ATGTGCAAGTCAGCTTCCCT
Mpzl1-B TGGCTGTGGTCGGTGCTA
Ntf3-F GCCACGGAGATAAGCAAGAA
Ntf3-B ACGGATGCCATGGTTACTTC
Foxo1-F ACGAGTGGATGGTGAAGAGC
Foxo1-B TGCTGTGAAGGGACAGATTG
Igfbp1-F TCCTCTGTCATCTCTGGGCT
Igfbp1-B TGTGTACCAGAACCTGCTGC
Pck1-F AGAAGGAGTACCCATTGAG
Pck1-B CTGAGGGCTTCATAGACA
G6pc-F ATG GTCACTTCTACTCTTGC
G6pc-B CAAGATGACGTTCAAACAC
Ppargc1a-F TGAAGTGGTGTAGCGACCAA
Ppargc1a-B CGCTAGCAAGTTTGCCTCAT
Gck-F TCACTGGCTGACTTGGCTTGCA
Gck-B AAGGACAGGGACCTGGGTTCCA
Srebf1-F GGA GCCATGGATTGCACATT
Srebf1-B CCTGTCTCACCCCCAGCATA
Fasn-F CTGCCACAACTCTGAGGACA
Fasn-B TTCGTACCTCCTTGGCAAAC
Acaca-F GGCCAGTGCTATGCTGAGAT
Acaca-B TATCACACAGCCAGGGTCAA
Srebf2-F ACAGCCGCCCTTCAAGTG
Srebf2-B TCACAGGCATTGTGGTCAGAA
Hmgcs1-F GCATTCAAAGGAAGTGACCC
Hmgcs1-B CGTTCTTCTTCCAGGGTCTG
Hmgcr-F AGAGCGAGTGCATTAGCAAAG
Hmgcr-B TCACAAGGCATTCCACAAGA
Pnpla2-F TCA TCA GGT CCT TTG GTT CC
Pnpla2-B TCC GAG AGA TGT GCA AAC AG
Lipe-F TCT CGT TGC GTT TGT AGT GC
Lipe-B ACG CTA CAC AAA GGC TGC TT
Hmgcs2-F GGT GGA TGG GAA GCT GTC TA
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Q-PCR primer
Hmgcs2-B ACA TCA TCG AGG GTG AAA GG
Affymetrix MoGene-2_0-st arrays
RNA was extracted using TRI reagent (Sigma) and then subjected to a cleanup step using an 
RNeasy Mini Kit with on-column DNase digestion (Qiagen). Gene expression profiles were 
obtained using Affymetrix MoGene-2_0-st Chip in Genetics Core facility of Boston 
Children’s Hospital.
Statistical Analysis
Two-tailed unpaired Student’s t-tests were used to assess statistical significance between two 
groups. Multiple groups or treatment were compared using one-way ANOVA or two-way 
ANOVA, or Kruskal-Wallis test as appropriate to the design and/or data distribution. When 
ANOVA indicated a significant difference among the groups, differences between groups 
were identified using a stricter criterion for significance according to the Bonferroni rule. 
Due to non-normal distribution of data in Fig 4b,d,e, data are reported as the median
±95%CI. No data were considered outliers by testing or arbitrarily excluded. The sample 
sizes (indicated throughout) were chosen to equal to three or greater for in vitro studies and 
five or greater (e.g. mice per group) for in vivo experiments. Data collection for screening of 
putative hepatokines (Fig. 2) in WT mice was performed in blind fashion and unblinded for 
treatment (hepatokine). Arrays (Supplemental Fig. 2i and Supplemental Fig. 8a) were 
performed by service for fee that was blind to genotype. GraphPad Prism 7 software was 
used for all data analysis.
Data Availability and Accession Code
Array Express accession number for data in Fig. 3b,c is #E-MEXP-1649. The data in 
Supplemental Fig. 2i and Supplemental Fig. 8a have been deposited in NCBI's Gene 
Expression Omnibus and are accessible through GEO Series accession number GSE111809.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Hepatic FoxO1 dysregulates WAT insulin signaling. (a,b) Glucose infusion rates (GIR) 
before and at steady-state (bar graphs) during hyperinsulinemic-euglycemic clamp of four-
month old LDKO and Cntr mice (n = 7) (a), or LTKO and Cntr3 mice (n = 8) (b). (c,d) 
Hepatic glucose production (HGP) in LDKO and Cntr mice (n = 7) (c) or LTKO and Cntr3 
mice (n = 8) (d) before and during the hyperinsulinemic-euglycemic clamp; inset shows the 
calculated suppression (%) of HGP by insulin. (e) Insulin-stimulated Irs1•p110PI3K complex 
formation in eWAT of four-month old LDKO, LTKO and control mice (n = 4–5). (f) Insulin-
stimulated Irs1•p110PI3K complex formation in eWAT of three-month old Irs1L/L•Irs2L/L 
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mice three weeks after injection with CreAAV•TBG or GFPAAV•TBG (n = 4–6). (g) Insulin-
stimulated Irs1•p110PI3K complex formation in eWAT of eighteen-week old LTKO and 
Cntr3 mice two weeks after injection with FoxO1AdV (n = 3–5). (h) Fasting blood glucose 
levels in two-month old FDKO and Irs1L/L•Irs2L/L mice two weeks after injection with 
CreAAV•TBG or control GFPAAV•TBG (n = 7–8). (i) Glucose tolerance of FDKO and 
Irs1L/L•Irs2L/L mice two weeks after CreAAV•TBG or GFPAAV•TBG injection; inset, areas 
under glucose curves (n = 5–6). Data were analyzed by one-way ANOVA (c,d,e,h,i) and 
unpaired Student’s t-test (a,b,c,d,f,g). All data are presented as mean ± SEM. *P < 0.05; **P 
< 0.01; ***P < 0.001; ****P < 0.0001.
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Figure 2. Identification of Fst315 as a hepatic FoxO1-regulated hepatokine regulating systemic 
glucose homeostasis
(a) Insulin-stimulated Irs1•p110PI3K complex formation in 3T3-L1 adipocytes cultured with 
serum from overnight fasted four-month old LDKO (vs Cntr) mice without (left, n = 8) or 
with heat inactivation of the serum (56°C for 45 min.) (right, n = 4). (b,c) Identified genes 
encoding putative hepatic secreted proteins that decreased (b) or increased (c) >3-fold in 
LDKO mice (Benjamini-Hochberg FDR<0.05). Several of these secreted proteins seemed 
likely to have effects upon peripheral metabolism (marked as *) were selected for functional 
screening in mice. (d–i) Five-week old C57BL6 mice were challenged with high fat diet 
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(45% fat) for 2 months, then infected with GFPAAV•TBG or hepatokineAAV•TBG (2×1011 
Genome Copy (GC)/mouse) encoding the indicated genes: fasting blood glucose (d) and 
fasting serum insulin (e) were measured one week after infection and used to calculate (f) 
HOMA2 IR as a measure of systemic insulin resistance (n = 5–10). (g) Insulin tolerance 
tests (ITT) were performed four weeks after infection with GFPAAV•TBG or 
hepatokineAAV•TBG and summarized by the areas under glucose curves (AUC) (n = 4–10). 
(h,i) Glucose tolerance tests were performed one week after AAV infection (h) and 
summarized (i) by the areas under glucose curves (AUC) (n = 4–10). (j) Fasting serum Fst 
levels measured four weeks after infection of HFD-fed C57BL6 mice with Fst315AAV•TBG 
or GFPAAV•TBG (n = 5). Data were analyzed by two-way ANOVA (h), one-way ANOVA 
(d,e,f,g,i) and unpaired Student’s t-test (a, j). Data are reported as the mean±SEM. *P<0.05; 
**P<0.01; ***P<0.001; ****P<0.0001.
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Figure 3. Fst expression and secretion is positively regulated by FoxO1, and down-regulated by 
gastric bypass surgery in obese diabetic individuals
(a) Relative expression of Fst315 and Fst288 mRNAs, or total Fst mRNA, measured by 
qPCR on liver RNA from four-month old LDKO and LTKO mice (n = 3–5). (b) Serum total 
Fst concentration in four-month old LDKO and LTKO mice (n = 7–10). (c) Representative 
images of liver sections from four-month old LDKO and control mice immunostained using 
antibody against Fst and DAPI to visualize nuclei (n = 2 from each group). Scale bars, left 
(500 µm); middle and right (50 µm). (d) Relative Fst gene expression in primary hepatocytes 
treated for 12 hours with or without glucagon (Gcg, 100nM) 48 hours after infection with 
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shFoxO1AdV or control shGFPAdV (n = 3). (e) Total Fst mRNA expression and protein 
concentration in cell lysates or culture medium of primary hepatocytes infected with 
FoxO1AdV or GFPAdV for 24 hours (n = 3). (f) Total Fst mRNA expression and protein 
concentration in cell lysates or medium of primary hepatocytes infected with shGFPAdV and 
shFoxO1AdV for 48 hours (n = 3). (g) Chromatin-immunoprecipitation (ChIP) with FoxO1 
antibody showing FoxO1 binds directly to the Fst promoter. (h,i) Serum HbA1c% (h) and 
total Fst concentration (i) in obese diabetic individuals before and 6 months after Roux-en-Y 
gastric bypass surgery (n = 9) (see Supplemental Table 2 for individual data). Data were 
analyzed by one-way ANOVA (a,b,d), unpaired Student’s t-test (e,f,g) and paired Student’s 
t-test (h,i). Data are reported as the mean±SEM. *P<0.05; **P<0.01; ***P<0.001; 
****P<0.0001.
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Figure 4. Knockdown of Fst improves WAT insulin sensitivity, reduces HGP and improves 
glucose tolerance in LDKO mice
Panels a–g: Two to three-month old LDKO mice were infected with ‘nullAAV•TBG’ 
(encoding luciferase) or with sgFstAAV•TBG (encoding small guide RNA sgFst1 or sgFst2) to 
effect partial hepatic Fst knockout (n = 7). (a,b) Hepatic Fst protein content (a) and serum 
total Fst concentration (b) were measured two weeks after infection. (c) GTTs were 
performed 10 days after infection and summarized by the areas under curves (AUC). (d) 
Fasting serum insulin levels were measured two weeks after infection. (e) Insulin-stimulated 
Irs1•p110PI3K complex formation in eWAT, measured two weeks after infection. (f,g) Insulin 
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regulated phosphorylation of Akt and HSL in eWAT was analyzed two weeks after infection 
by Western blotting (f) and quantitated by densitometry (g). Panels h–k: Five-month old 
LDKO mice were infected with ‘nullAAV•TBG’ or shFstAAV•TBG (encoding a miRNA-like 
hairpin RNA against Fst) and hyperinsulinemic-euglycemic clamps were conducted four 
weeks later (n = 5). (h and i) Blood glucose concentrations (h) and glucose infusion rates (i) 
before and at steady-state during hyperinsulinemic-euglycemic clamp. (j,k) Basal and 
clamped hepatic glucose production (j) and calculated suppression of HGP by insulin during 
the clamp (k). Panels l–n: Five weeks of C57BL6 mice maintained on high fat diet for two 
months were infected with shFstAAV-TBG or NullAAV-TBG (n = 7). Serum Fst levels were 
measured two weeks after infection (l); GTTs (m) and fasting blood glucose levels (n) were 
measured ten days after infection. Data (b,d,e) were reported as the median±95%CI, and 
Kruskal-Wallis test was used to identify significant differences between treatments of LDKO 
mice. Other data were reported as the mean±SEM. Data were analyzed by One-way 
ANOVA (a,c,g,j), two-way ANOVA (i) and unpaired Student’s t-test (k,l,m,n). P<0.05; 
**P<0.01; ***P<0.001; ****P<0.0001.
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Figure 5. Fst315 promotes WAT insulin resistance, HGP, and glucose intolerance in WT mice
(a) Insulin-stimulated Irs1•p110PI3K complex formation in 3T3-L1 adipocytes treated with 
serum from overnight-fasted four-month old LDKO (vs Cntr) mice, with or without the 
addition of Fst antibody (R&D, AF669, 10 µg/ml) (n = 5–6). Panels b–k: Five-week old 
C57BL6 mice were challenged with high fat diet for four months before infection with 
Fst315AAV•TBG or GFPAAV•TBG, and hyperinsulinemic-euglycemic clamps were performed 
four weeks later. (b–e) Uptake of 2DOG ([1-14C] 2-deoxy-D-glucose) tracer into eWAT (b), 
iWAT (c), skeletal muscle (d), and BAT (e), measured at the end of the clamp (n = 6). (f,g) 
Western blot analysis (f) and densitometric quantitation (g) of insulin-regulated Akt and 
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HSL phosphorylation in eWAT upon completion of the clamp. (h,i) Blood glucose 
concentrations (h) and glucose infusion rates (i) before and during hyperinsulinemic-
euglycemic clamp (n = 6). (j,k) Basal and clamped hepatic glucose production (j), and 
calculated suppression of HGP by insulin during the clamp (k) (n = 6). (l) Change in serum 
FFAs (% of overnight-fasted baseline) following insulin treatment (1 U/kg, i.p.) of 14-week 
old C57BL6 mice (maintained 10 weeks on high fat diet) two weeks after infection with 
Fst315AAV•TBG or GFPAAV•TBG (n = 10). (m) Change in serum FFAs (% of overnight-fasted 
baseline) following insulin treatment (1 U/kg, i.p.) of four-month old LTKO mice two weeks 
after infection with Fst315AAV•TBG or GFPAAV•TBG (n = 6–7). (n) Urinary ketones in four-
month old LDKO and control mice after five hour fast (n = 10–12). (o) Urinary ketones (5 
hours fasting) in four-month old LTKO and control mice two weeks after infection with 
GFPAAV•TBG or Fst315AAV•TBG (n = 8). Data in (a) were analyzed by ANOVA and 
compared by the FDR method of Benjamini and Hochberg (*q < 0.05); other data were 
analyzed by unpaired Student’s t-test (b–e,g,k,n), one-way ANOVA (j and o) and two-way 
ANOVA (i,l,m). Data are reported as the mean±SEM. *P<0.05; **P<0.01; ***P<0.001; 
****P<0.0001.
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Figure 6. Regulation of hepatic gene expression by Fst depends partially on hepatic FoxO1
Panels a–d: C57BL6 mice challenged with high fat diet for 2 months were infected with 
Fst288AAV•TBG or GFPAAV•TBG. (a,b) Hepatic mRNA expression was measured by qPCR 
after a 16 h overnight fast without (a) or with 4 hours of refeeding (b) one week after AAV 
infection. (c) Glucose-6-phosphatase (G6Pase) activity after a 16 h overnight fast in liver 
one week after infection with Fst288AAV•TBG or GFPAAV•TBG (n = 5). (d) Western blot 
analysis and densitometric quantitation of FoxO1 protein in nuclear and cytoplasmic 
fractions, or total liver lysate of C57BL6 mice, with or without 4 hours refeeding following a 
16 h overnight fast, and one week after infection with Fst288AAV•TBG or GFPAAV•TBG (n = 
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5). Panels e–i: Two-month old LTKO mice were infected with GFPAAV•TBG or 
Fst288AAV•TBG to reconstitute hepatic Fst. GTTs (e) were performed two weeks after AAV 
infection (n = 7). (f,g) Hyperinsulinemic-euglycemic clamps were conducted four weeks 
after infection; shown are the blood glucose concentrations (f) and glucose infusion rates 
before and at steady state (g) during hyperinsulinemic-euglycemic clamp (n = 5). (h,i) Basal 
and clamped hepatic glucose production (h) and calculated suppression of HGP by insulin 
during the clamp (i) (n = 5). Data were analyzed by unpaired Student’s t-test (a–e,g,i) and 
one-way ANOVA (h). Data are reported as the mean ± SEM. *P<0.05; **P<0.01; 
***P<0.001; ****P<0.0001.
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